The design and performance of stormwater controls is affected by the treatment flow rates of bioretention media. This article presents the results of a large number of laboratory column tests ...
On Wednesday, Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). ALLIANCE is ...
FOSTER CITY, Calif., March 12, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative ...
Harnessing Real-World Data and AI to Advance Research and Treatment for Benign Prostatic Hyperplasia
Benign prostatic hyperplasia (BPH) is one of the most common urologic conditions affecting men as they age, with nearly 50% of men over 50 experiencing symptoms. Despite its prevalence, treatment ...
– Investigational Long-Acting, Twice-Yearly Treatment Regimen of Lenacapavir and Broadly Neutralizing Antibodies (bNAbs) Meets Primary Endpoint in Phase 2 Study and Gains Breakthrough Therapy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback